Protalix BioTherapeutics, Inc. (PLX) stock
PLXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 16/3044% below fair value
$2.88−0.15 (-4.95%)
Close on Nov 17, 2026Market cap $232.05MP/E 12.5Yield –
Protalix BioTherapeutics pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Protalix BioTherapeutics's pe ratio was 13.6× on Nov 11, 2026, against 38.8× a year earlier. Over the last 4 years it ranged from 0.9× to 155.0×, with a median of 18.1×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 13.6× | −31.4 |
| 2025 | Dec 31, 2025 | 45.0× | +23.4 |
| 2024 | Jul 31, 2024 | 21.6× | −14.0 |
| 2023 | Dec 29, 2023 | 35.6× | +34.3 |
| 2017 | Jan 31, 2017 | 1.3× | +0.4 |
| 2016 | Dec 30, 2016 | 1.0× | – |
See a number that looks wrong?